Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accessibility and harmonization of biochemical tests for diagnosis and monitoring of Porphyrias in the United States: Recommendations by members of the American Porphyrias Expert Collaborative (APEX).

Molecular genetics and metabolism·2026
Same author

Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia.

Research and practice in thrombosis and haemostasis·2025
Same author

Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination.

Bone marrow transplantation·2022
Same author

ABCB6 polymorphisms are not overly represented in patients with porphyria.

Blood advances·2021
Same author

Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2021
Same author

How Do Red Blood Cells Die?

Frontiers in physiology·2021
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore
09:15

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Published on: January 21, 2020

Paroxysmal nocturnal hemoglobinuria.

Charles J Parker1

  • 1Division of Hematology and Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA. Charles.Parker@hsc.utah.edu

Current Opinion in Hematology
|March 8, 2012
PubMed
Summary
This summary is machine-generated.

Eculizumab treatment offers a benign clinical course for paroxysmal nocturnal hemoglobinuria (PNH) patients, with survival comparable to the general population. Novel therapies targeting complement C3 convertase aim to inhibit PNH hemolysis.

More Related Videos

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

Near-Infrared Spectroscopy During Reactive Hyperemia for the Assessment of Lower Limb Vascular Function
04:44

Near-Infrared Spectroscopy During Reactive Hyperemia for the Assessment of Lower Limb Vascular Function

Published on: March 22, 2024

Related Experiment Videos

Last Updated: May 24, 2026

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore
09:15

Induction of Eryptosis in Red Blood Cells Using a Calcium Ionophore

Published on: January 21, 2020

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

Near-Infrared Spectroscopy During Reactive Hyperemia for the Assessment of Lower Limb Vascular Function
04:44

Near-Infrared Spectroscopy During Reactive Hyperemia for the Assessment of Lower Limb Vascular Function

Published on: March 22, 2024

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired blood disorder characterized by complement-mediated hemolysis.
  • PNH is associated with significant morbidity and mortality due to thrombotic complications and bone marrow failure.
  • Understanding the natural history and therapeutic landscape of PNH is crucial for patient management.

Purpose of the Study:

  • To review recent observations on the natural history of paroxysmal nocturnal hemoglobinuria (PNH).
  • To evaluate new therapeutic strategies for controlling hemolysis in PNH.
  • To assess the long-term outcomes of PNH patients treated with eculizumab.

Main Methods:

  • Review of studies on long-term outcomes of eculizumab-treated PNH patients.
  • Analysis of the relationship between PNH and bone marrow failure syndromes.
  • Examination of novel therapeutic strategies targeting extravascular and intravascular hemolysis.

Main Results:

  • Eculizumab demonstrates long-term safety and efficacy in PNH patients, with survival not differing from the general population.
  • Thrombotic complications and PNH-related deaths were rare in eculizumab-treated patients.
  • Patients with bone marrow failure and PNH cells often have aplastic anemia or MDS; subclinical PNH clones do not typically expand to cause clinical disease.

Conclusions:

  • Eculizumab treatment leads to a benign clinical course for patients with clinical PNH.
  • Approximately 50% of PNH patients with bone marrow failure may require PNH-specific therapy.
  • New complement C3 convertase inhibitors are under development to address both extravascular and intravascular hemolysis in PNH.